US1420381089 - Common Stock
CARIBOU BIOSCIENCES INC
NASDAQ:CRBU (5/10/2024, 7:00:01 PM)
After market: 3.55 +0.01 (+0.28%)3.54
-0.11 (-3.01%)
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 137 full-time employees. The company went IPO on 2021-07-23. The firm is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients with devastating diseases. The Company’s CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), enables superior genome-editing precision to develop cell therapies that are specifically engineered for enhanced persistence. The company is advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (CAR)-T (CAR-T) and CAR-natural killer (CAR-NK) cell therapies for the treatment of patients with hematologic malignancies and solid tumors. The Company’s lead product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 CAR-T cell therapy with programmed cell death protein 1 (PD-1) removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. The Company’s product candidate also includes CB-011, CB-012 and CB-020.
CARIBOU BIOSCIENCES INC
2929 7Th Street, Ste 120
Berkeley CALIFORNIA
P: 15109826030
Employees: 137
Website: https://www.cariboubio.com/
CRBU stock results show that Caribou Biosciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Caribou Biosciences (NASDAQ:CRBU) just reported results for the first quarter o...
Here you can normally see the latest stock twits on CRBU, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: